Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) have earned an average recommendation of “Buy” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have covered the stock in the last […]
Tekla Capital Management LLC cut its holdings in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) by 57.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 43,394 shares of the company’s stock after selling 58,537 shares during the quarter. Tekla Capital Management LLC […]